A potential COVID-19 survival benefit is suggested in association with initiation or continuation of an angiotensin-converting enzyme inhibitor (ACE-I), an angiotensin receptor blocker (ARB), or metformin for hospitalized patients, according to a study published in the December issue of The BMJ. Arthur W. Wallace, M.D., Ph.D. and colleagues classified patterns of ACE-I, ARB, beta-blocker, metformin, famotidine, and remdesivir use and captured mortality among 9,532 hospitalized patients with COVID-19 infection. The researchers found that discontinuation of an ACE-I was associated with an elevated risk for death (odds ratio, 1.4), while the risk for death was reduced in association with initiating or...